© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco
A recent analysis of two studies of AbbVie’s hepatitis C regimen showed good results in this population.
In a recent study of Gilead’s Epclusa (sofosbuvir/velpatasvir), 92 percent of participants were on dialysis and 29 percent had cirrhosis.
Researchers crunched the numbers for transplanting kidneys from donors with hep C and then treating the virus in the recipient.
This is according to a large study of Swedish people with hep C and chronic kidney disease.
And can treating the virus reduce the risk of chronic kidney and cardiovascular diseases as well as the risk of death from such causes?
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
